CLXPF News and Press, Canadian Lynx Pete Ltd From 06/25/21

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The firesi...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a virtual fireside ...

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatmen...

In the recent past, numerous studies have focused on the clinical application of psychedelics, including LSD, ayahuasca and psilocybin, in treating anxiety and depression disorders being conducted. For example, University of Zurich researchers have demonstrated that mindfulness meditation ...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the addition of Dr. Thomas Laughren, to the Clinical Advisory Board. Dr. Thomas Laug...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of ...

TORONTO, June 23, 2021 (GLOBE NEWSWIRE) -- Cybin Inc. ( NEO:CYBN ) ( OTCQB:CLXPF ) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51 st pre-clinical study as it continues to progress its p...